Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)
Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD
The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.
This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:
Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Linyi Peng
- Phone Number: +86-10-69155004
- Email: drpenglinyi@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All IgG4-related disease patients treated with inebilizumab.
Description
Inclusion Criteria:
- Aged ≥18 years old;
- Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
- Plan to receive treatment with inebilizumab;
- Signed informed consent form.
Exclusion Criteria:
- Pregnant or lactating female patients;
- Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
- Patients with contraindications to inebilizumab treatment;
- Any other conditions deemed inappropriate for enrollment by the investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: CROSS_SECTIONAL
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with IgG4-RD treated with inebilizumab
Patients with IgG4-RD receiving inebilizumab in the real-world setting |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relapse rate
Time Frame: One year after inebilizumab treatment
|
Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index |
One year after inebilizumab treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of subjects achieving flare-free and treatment-free complete remission
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Remission rate after inebilizumab treatment
Time Frame: Six months and twelve months after inebilizumab treatment
|
The investigator determined that there was no evidence of disease activity at the visit |
Six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Responder Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Damage Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum B-cell levels from baseline after inebilizumab treatment
Time Frame: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Total amount of glucocorticoids during inebilizumab administration
Time Frame: One year after inebilizumab treatment
|
Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period. |
One year after inebilizumab treatment
|
|
Improvement in patients' quality of life during inebilizumab administration
Time Frame: One year after inebilizumab treatment
|
Quality of life measured by the EQ-5D-5L questionnaire |
One year after inebilizumab treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I-26PJ0909
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.